Eupraxia Pharmaceuticals Inc. cash flow to debt ratio of -18.81K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Eupraxia Pharmaceuticals Inc.'s free cash flow has increased -1.57% from $-30.10M last year to $-29.63M, signaling increasing performance

Eupraxia Pharmaceuticals Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Eupraxia Pharmaceuticals Inc.'s debt has increased relative to shareholder equity from 0.00 last year to 0.01 today, signaling weakened financials

Eupraxia Pharmaceuticals Inc. has a net cash position, so leverage is healthy.

Eupraxia Pharmaceuticals Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Eupraxia Pharmaceuticals Inc. has insufficient data to evaluate this check.

Eupraxia Pharmaceuticals Inc.'s short-term assets of $85.10M exceed its short-term liabilities of $5.63M

Eupraxia Pharmaceuticals Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Eupraxia Pharmaceuticals Inc.'s return on equity of -53.61%, is lower than 15.00%, indicating bad performance

Eupraxia Pharmaceuticals Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Eupraxia Pharmaceuticals Inc. has insufficient public price history to evaluate earnings stability.

Eupraxia Pharmaceuticals Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Eupraxia Pharmaceuticals Inc. has negative free cash flow, indicating cash burn

Eupraxia Pharmaceuticals Inc.'s yearly earnings has decreased 111.33% since last year from $-25.49M to $-53.86M, signaling decreasing performance

Eupraxia Pharmaceuticals Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -34.12% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Eupraxia Pharmaceuticals Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Eupraxia Pharmaceuticals Inc. has insufficient public price history to evaluate revenue consistency.

Eupraxia Pharmaceuticals Inc. has insufficient public price history to evaluate ROE consistency.

Eupraxia Pharmaceuticals Inc. is overvalued relative to its fair value price of 1.76 based on Discounted Cash Flow model

Eupraxia Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Eupraxia Pharmaceuticals Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Eupraxia Pharmaceuticals Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Eupraxia Pharmaceuticals Inc. has insufficient data to evaluate this check.

Eupraxia Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Eupraxia Pharmaceuticals Inc. has a price-to-book ratio of 2.77x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Eupraxia Pharmaceuticals Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue